logo BDSP

Base documentaire

  1. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure.

    Article - En anglais


    Chronic heart failure is associated with a poor prognosis and reduced survival rates.

    The addition of vasodilator drug therapy to conventional therapy for congestive heart failure has resulted in improved survival.


    Adopting a societal viewpoint, we designed a decision analytic model to analyze the costs and effectiveness of three therapies available for the treatment of congestive heart failure : standard therapy (digoxin and diuretic therapy) plus (1) no vasodilator agents, (2) hydralazine hydrochloride-isosorbide dinitrate combination, and (3) enalapril.

    Mots-clés Pascal : Insuffisance cardiaque, Peptidyl-dipeptidase A, Peptidyl-dipeptidases, Proteinases, Hydrolases, Enzyme, Inhibiteur enzyme, Chimiothérapie, Traitement, Vasodilatateur, Homme, Analyse coût efficacité, Economie santé, Appareil circulatoire pathologie, Cardiopathie

    Mots-clés Pascal anglais : Heart failure, Peptidyl-dipeptidase A, Peptidyl-dipeptidases, Proteinases, Hydrolases, Enzyme, Enzyme inhibitor, Chemotherapy, Treatment, Vasodilator agent, Human, Cost efficiency analysis, Health economy, Cardiovascular disease, Heart disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 94-0494437

    Code Inist : 002B02F04. Création : 199501.